(Registrieren)

EANS-News: DEWB investment holding Nanda Technologies raises 4m USD in a financing round led by Capital-E and KfW

Geschrieben am 09-04-2010


--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------


Company Information

Germany/Belgium, April 09, 2010 (euro adhoc) - Capital-E, a Belgium
based Venture Capital company focussing on semiconductor investments,
and KfW with his ERP Start-up-Fund, one of the largest German VC
funds, are investing alongside with the existing shareholders about
4m USD in Nanda Technologies GmbH. Capital-E will take an active part
in the board to support the further growth of Nanda. Other investors
include the existing shareholders Brains-to-Ventures, Ventegis
Capital AG, Bayern Kapital and DEWB.

Nanda was founded in 2006 and has successfully developed a new system
for highthroughput full wafer inspection used in semiconductor
manufacturing. Based on a proprietary optical design combined with
innovative image processing software Nanda can drastically increase
the speed of inspection while maintaining high sensitivity. The
result is a significant decrease in inspection cost per wafer
compared to existing tools and the inspection of every wafer in the
process flow instead of sampling only a few. The compact design of
Nanda´s inspection system makes it attractive to integrate defect
inspection directly into the production flow. Fast error-feedback
permits accelerated process adjustments and thus increases process
ramp-up and overall productivity. After having successfully installed
a first system at a leading industry backed research institute Nanda
is working with global semiconductor manufacturers to evaluate the
tools for production.

"Despite a difficult year in 2009, Nanda has achieved a first tool
installation and very promising engagements on the customer side. We
were convinced by the market opportunity and the unique technology,
which gives Nanda a sustainable competitive edge", comments Pascal
Vanluchene, Partner at Capital-E. Due to his close links to IMEC and
prior investments in micro-electronics ventures, Pascal will take an
active role in helping Nanda to grow its business.

"Coming out of a deep recession in 2009, the timing is good for Nanda
to execute on a broad market entry in 2010 and 2011. We are happy to
have Capital-E and KfW on board to ensure enough liquidity during
this critical phase for every start-up company", says Dr. Christian
Reitberger, chairman of the board.

"With the two new investors on board we have a strong shareholder
base that could provide, if needed, additional financing throughout
break-even of the company. This helps us to focus on market entry and
customer interactions", adds Johannes von Borries, CFO/COO. Nanda
will use the proceeds to support pre-production evaluations at
leading semiconductor manufacturers.

About Nanda Technologies Nanda Technologies offers its customers in
the semiconductor industry a high throughput, high sensitivity defect
inspection system. Based on a unique optical technology it is
possible to inspect the full surface of the wafer and every wafer in
the process flow instead of conducting statistical sampling. The
feedback cycle for process faults is reduced significantly and
process equipment malfunctions are caught and identified at an early
stage. Nanda Technologies was founded in Munich by seasoned
executives of the capital metrology equipment industry and supplies
the inspection tools to leading semiconductor manufacturers
worldwide.

Contact
Johannes von Borries
Lise-Meitner-Str. 3
85716 Unterschleissheim
Tel: +49 89 4523558-21

About Capital-E Capital-E is an early stage venture fund focused
exclusively on micro- and nano-electronics related start-ups in
Europe. Through its entrenched relationship with IMEC, the largest
independent research centre in micro- and nanoelectronics in Europe,
the fund and its ventures can directly rely on the support of over
1500 specialised scientists and engineers, as well as leverage on
IMEC s 500+ worldwide industrial partners such as NXP, Infineon,
STMicroelectronics, Intel, Micron, Matsushita/Panasonic, Texas
Instruments, Samsung and TSMC to speed-up the process of market
entry. The fund is managed by an independent team with a balanced mix
of entrepreneurial, industrial and VC experience. www.capital-e.com

About KfW KfW finances and supports, among other things, business
start-ups, small and medium-sized enterprises (SME) as well as
investments in economic growth and employment projects in Germany.
The ERP Start-up-Fund, administered and co-financed by KfW, offers
equity financing for innovative, technology-based enterprises with
excellent growth prospects. The fund finances research and product
development as well as the launching of new products, procedures and
services. KfW always cooperates with a lead investor and exclusively
adopts market conditions. Since 2004; the 470 million Euro ERP
Start-up-Fund has so far allocated 300 million Euro to emerging
technology-based companies. www.kfw-mittelstandsbank.de

About DEWB Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG
(DEWB AG, General Standard, Securities No.: 804100 / ISIN:
DE0008041005) is an investment company that specialises in young and
established medium-sized companies. The focus of our investments is
on strong growth companies from the areas of photonics and sensor
systems for which we provide support through shareholders' equity,
expertise in corporate development and our sector network. Our
regional focus lies in the German speaking countries (D, A, CH).
Since 1997 we have invested more than 300 million Euros in 55
companies and realized more than 400 million Euros through 36 exits,
eight of which were in the form of IPOs. The company is located in
Jena, one of the most successful technology and science regions in
Germany, with a long tradition in the field of optical technologies
and one of the most important European centres for photonics.
www.dewb-vc.de

About b-to-v BrainsToVentures AG (b-to-v) is headquartered in St.
Gallen, Switzerland. The company serves entrepreneurial private
investors who invest their capital, network and expertise in
fast-growing companies. By making this pool of capital, contacts and
expertise available to portfolio companies, b-to-v has established a
new business model in the venture capital and private equity
industry. With over 50 members, the b-to-v Investors Circle is the
most active club of entrepreneurial private investors in
German-speaking Europe. Based on the members´ expertise, b-to-v´s
scope of investment comprises more than 30 different industries. It
is the goal of the Investors Circle to create value for its portfolio
companies and generate significant profits from its investments.
b-tov´s Investors Circle invests about EUR 20m per year in early and
expansion stage companies as well as buyout cases. At present, b-to-v
is invested in about forty companies. Investments vary between EUR
500k and 3m per deal. www.b-to-v.com

About Ventegis Capital AG Ventegis Capital AG is a listed venture
capital company which invests nationally in high-growth companies
from the early to the expansion stage. The focus of its investments
lies in the areas of information and communication technology (ICT),
industrial technologies and life science. Ventegis also provides
advisory services in corporate finance. The main shareholder of the
company with ca. 94.3 % is the Berliner Effektengesellschaft AG,
which is listed on the official market (ISIN DE0005221303).
www.ventegis-capital.de

About Seedfonds Bayern und Technofonds Bayern III managed by Bayern
Kapital The Seedfonds Bayern an the Technofonds Bayern III are
managed by Bayern Kapital which was founded in 1995 by the Bavarian
Government as part of the campaign "Initiative Bavarian Future" and
to provide young and innovated Bavarian companies with venture
capital. Up to date Bayern Kapital has invested in over 180
innovative high-tech companies with a total investment volume of
about 150m EUR. More information under: www.bayernkapital.de

About High-Tech Gruenderfonds The High-Tech Gruenderfonds invests
venture capital in young technology companies with high prospects
that are transferring promising scientific research to business
enterprises. The seed financing shall result in a technical
prototype, a proof of concept or a market launch. High-Tech
Gründerfonds has access to a fund volume of around 272,0 million
Euro. Investors in this publicprivate partnership include the Federal
Ministry for Economy and Technology, the KfW Banking Group as well as
the six industry companies BASF, Robert Bosch, Carl Zeiss, Daimler,
Deutsche Telekom and Siemens. www.high-tech-gruenderfonds.de


end of announcement euro adhoc
--------------------------------------------------------------------------------


ots Originaltext: Deutsche Effecten- und Wechsel-Beteiligungsges. AG (DEWB)
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Marco Scheidler

Tel.: +49 (0) 3641 573-3600

E-Mail: marco.scheidler@dewb-vc.com

Branche: Financial & Business Services
ISIN: DE0008041005
WKN: 804100
Index: CDAX, Classic All Share, Prime All Share
Börsen: Berlin / free trade
Stuttgart / free trade
München / free trade
Frankfurt / regulated dealing/general standard


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

261497

weitere Artikel:
  • EANS-Stimmrechte: Nordex SE / Veröffentlichung gemäß § 26 Abs. 1 Satz 1 WpHG mit dem Ziel der europaweiten Verbreitung -------------------------------------------------------------------------------- Stimmrechtsmitteilung übermittelt durch euro adhoc mit dem Ziel einer europaweiten Verbreitung. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- Angaben zum Mitteilungspflichtigen: ----------------------------------- Name: siehe Mitteilungstext Sitz: siehe Mitteilungstext Staat: siehe Mitteilungstext Angaben zum Emittenten: ----------------------- Name: Nordex mehr...

  • Berliner Wohnimmobilienunternehmen GSW Immobilien AG plant Börsengang im zweiten Quartal 2010 Berlin (ots) - - Ein führendes privates Wohnimmobilienunternehmen in Berlin strebt eine Notierungsaufnahme im Regulierten Markt (Prime Standard) der Frankfurter Wertpapierbörse und an der Berliner Börse an - Nettoersterlös soll die Eigenkapitalbasis der GSW stärken, die Loan-to-Value-Ratio verringern, zur Begleichung zinstragender EK02 Steuerverbindlichkeiten verwendet werden sowie das Unternehmen mit größerer Flexibilität bei der Finanzierung des angestrebten Wachstums ausstatten - Deutsche Bank mehr...

  • Berlin residential real estate company GSW Immobilien AG plans IPO in second quarter of 2010 Berlin (ots) - - A leading privately-owned residential real estate company in Berlin intends to list on the Regulated Market (Prime Standard segment) of the Frankfurt Stock Exchange and on the Berlin Stock Exchange - Net primary proceeds to strengthen GSW's capital base, reduceoverall loan-to-value ratio, pay off interest bearing EK02 tax liabilities and provide the Company with greater flexibility in financing its planned growth - Deutsche Bank and Goldman Sachs International acting as Joint mehr...

  • aktien-meldungen.de: MediGene: "Fortschritte mit allen wichtigen Projekten gemacht" - CEO Dr. Frank Mathias im Interview Hamburg (ots) - Das Münchener Biotechnologieunternehmen MediGene (ISIN: DE0005020903 / WKN: 502090) erforscht, entwickelt und vermarktet Medikamente zur Behandlung von Krebs- und Immunerkrankungen. Im Interview mit a|m spricht der Vorstandsvorsitzende Dr. Frank Mathias über die Ziele des Unternehmens. a|m: Herr Dr. Mathias, mit Teva, Solvay und Meditrina konnten Sie namhafte Partner für die Vermarktung von Veregen® gewinnen. Welches Umsatzpotential hat das Medikament? Dr. Frank Mathias: Vielen Dank. Das Interesse ist weltweit mehr...

  • EANS-News: Nordex erhält Auftrag für Großprojekt in Schweden Lieferung von 295 MW für Projekte von Skelleftea Kraft AB -------------------------------------------------------------------------------- Corporate News übermittelt durch euro adhoc. Für den Inhalt ist der Emittent/Meldungsgeber verantwortlich. -------------------------------------------------------------------------------- Unternehmen Utl.: Lieferung von 295 MW für Projekte von Skelleftea Kraft AB Norderstedt (euro adhoc) - Nordex hat mit dem öffentlichen Energieversorger Skelleftea Kraft AB, Skelleftea, einen Rahmenvertrag für die mehr...

Mehr zu dem Thema Finanzen

Der meistgelesene Artikel zu dem Thema:

Century Casinos wurde in Russell 2000 Index aufgenommen

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht